Clinical Trials

Inclusion Criteria:

• Patient must be 18 years of age or older.
• Documented CD20+ mature B-cell neoplasm:
  • Diffuse large B-cell lymphoma - de novo or transformed;
  • High-grade B-cell lymphoma (Swerdlow et al., 2016);
  • Primary mediastinal large B-cell lymphoma;
  • Follicular lymphoma;
  • Mantle cell lymphoma;
  • Small lymphocytic lymphoma;
  • Marginal zone lymphoma (nodal, extranodal or mucosa associated).
• Relapsed, progressive and/or refractory disease following treatment with an anti-CD20 monoclonal antibody (e.g., rituximab) potentially in combination with chemotherapy and/or relapsed after autologous stem cell rescue.
• Documentation of CD20+ mature B-cell neoplasm based on any representative pathology report.
• Patients must have measurable disease by Computer Tomography (CT), Magnetic Resonance Imaging (MRI) or Positron Emission Tomography(PET)/CT scan.
• Acceptable renal function.
• Acceptable liver function.

Exclusion Criteria:

• Primary central nervous system (CNS) lymphoma or known CNS involvement by lymphoma.
• Known clinically significant cardiac disease:
  • Chronic ongoing infectious diseases (except hepatitis B or hepatitis C) requiring treatment (excluding prophylactic treatment).
• Eligible for curative salvage therapy with high dose therapy followed by stem cell rescue.
• Active hepatitis B or hepatitis C.
• Known human immunodeficiency virus (HIV) infection.
• Exposed to live or live attenuated vaccine within 4 weeks prior to signing Informed Consent Form (ICF).